Pharmacy and Therapeutics Committee
"Pharmacy and Therapeutics Committee" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An advisory group composed primarily of staff physicians and the pharmacist which serves as the communication link between the medical staff and the pharmacy department.
- Committee, Drug
- Drug Committees
- Drug Committee
- Committee, Formulary
- Committees, Formulary
- Formulary Committees
- Formulary Committee
- Committee, Pharmacy
- Committees, Pharmacy
- Pharmacy Committee
- Pharmacy Committees
- Committee, Therapeutics
- Committees, Therapeutics
- Therapeutics Committees
- Therapeutics Committee
- Committees, Drug
Below are MeSH descriptors whose meaning is more general than "Pharmacy and Therapeutics Committee".
Below are MeSH descriptors whose meaning is more specific than "Pharmacy and Therapeutics Committee".
This graph shows the total number of publications written about "Pharmacy and Therapeutics Committee" by people in this website by year, and whether "Pharmacy and Therapeutics Committee" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Pharmacy and Therapeutics Committee" by people in Profiles.
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9.
The investigational drug steering committee. Clin Adv Hematol Oncol. 2007 Oct; 5(10):779-80.
A call for fairness in formulary decisions. Arch Intern Med. 2006 Jan 09; 166(1):16-8.